Furthermore, when ROS exceeds a certain threshold, it leads to oxidative stress (6, 7)
The normality assumptions of models were visually checked where appropriate
and reduced BMI (7%), waist circumference (3%), and abdominal fat (17%) (Aziz, Hussain, Mahwi, Ahmed, Rahman 2018)
Similar content being viewed by others Background Glucagon-like peptide-1 (GLP-1) receptor agonists, exenatide, lixisenatide, liraglutide, dulaglutide and semaglutide, are among the recent subcutaneous treatment options that provide better glycemic improvement and weight loss in patients with type 2 diabetes according to the current guidelines [1, 2]